{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T04:43:16Z","timestamp":1786164196213,"version":"build-2736575974"},"reference-count":76,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Cannabidiol (CBD) has attracted growing scientific and clinical interest due to its potential therapeutic applications and increasing availability across Europe. This narrative review examined the regulatory status, market availability, and clinical use of CBD in Croatia in relation to selected European Union countries and international reference models (Canada and Australia). A literature search was conducted using PubMed, Scopus, and Web of Science, complemented by official regulatory and governmental sources. The analysis included Croatia, Germany, the Netherlands, Slovenia, Italy, France, and Finland, while Canada and Australia were discussed as international reference models. Considerable differences were identified regarding the regulation of CBD-containing products, access to medical cannabis, reimbursement policies, clinical implementation, and the role of pharmacists. Germany and the Netherlands have established well-developed systems for medical cannabis use, whereas Finland represents a more restrictive regulatory model. In Croatia, CBD-containing products are widely available, but their integration into routine clinical practice remains limited. Regulatory uncertainty, insufficient professional training, and the lack of standardised clinical guidance were identified as important barriers. The findings suggest that the expansion of the consumer CBD market has generally outpaced the integration of cannabinoid-based therapies into healthcare practice across the countries included in this review. Improved professional training and clearer clinical guidance may facilitate their evidence-based implementation in clinical practice.<\/jats:p>","DOI":"10.3390\/jcm15156123","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T13:03:27Z","timestamp":1786021407000},"page":"6123","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Regulation and Use of Cannabidiol in Croatia Compared with Selected European and International Models: From Consumer Products to Clinical Practice"],"prefix":"10.3390","volume":"15","author":[{"given":"Ana","family":"Batinic","sequence":"first","affiliation":[{"name":"Pharmacy of Split-Dalmatia County, 21000 Split, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6583-6722","authenticated-orcid":false,"given":"Antonia","family":"Zecic","sequence":"additional","affiliation":[{"name":"Department of Natural and Biomedical Sciences, Faculty of Forensic Sciences, University of Split, 21000 Split, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeljko","family":"Dujic","sequence":"additional","affiliation":[{"name":"Department of Integrative Physiology, School of Medicine, University of Split, 21000 Split, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9899-5119","authenticated-orcid":false,"given":"Davorka","family":"Sutlovic","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, University of Split, 21000 Split, Croatia"},{"name":"Department of Applied Pharmacy, School of Medicine, University of Split, 21000 Split, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Simei, J.L.Q., Souza, J.D.R., Pedrazzi, J.F., Guimar\u00e3es, F.S., Campos, A.C., Zuardi, A., Hallak, J.E.C., and Crippa, J.A.S. (2024). Research and Clinical Practice Involving the Use of Cannabis Products, with Emphasis on Cannabidiol: A Narrative Review. Pharmaceuticals, 17.","DOI":"10.3390\/ph17121644"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Barton\u010d\u00edkov\u00e1, M., Lap\u010d\u00edkov\u00e1, B., Lap\u010d\u00edk, L., and Valenta, T. (2023). Hemp-Derived CBD Used in Food and Food Supplements. Molecules, 28.","DOI":"10.3390\/molecules28248047"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"116605","DOI":"10.1016\/j.indcrop.2023.116605","article-title":"The phenological stage of hemp inflorescences affects essential oil yield and its chemical composition","volume":"197","author":"Pieracci","year":"2023","journal-title":"Ind. Crops Prod."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Liu, Z. (2025). Cannabidiol (CBD) and Colorectal Tumorigenesis: Potential Dual Modulatory Roles via the Serotonergic Pathway. Curr. Oncol., 32.","DOI":"10.3390\/curroncol32070375"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1089\/can.2016.0027","article-title":"The Name of Cannabis: A Short Guide for Nonbotanists","volume":"1","author":"Pollio","year":"2016","journal-title":"Cannabis Cannabinoid Res."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Duczmal, D., Bazan-Wozniak, A., Niedzielska, K., and Pietrzak, R. (2024). Cannabinoids-Multifunctional Compounds, Applications and Challenges-Mini Review. Molecules, 29.","DOI":"10.3390\/molecules29204923"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/sj.bjp.0707442","article-title":"The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin","volume":"153","author":"Pertwee","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s40122-024-00643-0","article-title":"Clinical Benefits and Safety of Medical Cannabis Products: A Narrative Review on Natural Extracts","volume":"13","author":"Mick","year":"2024","journal-title":"Pain Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1124\/jpet.121.000988","article-title":"Preclinical Assessment of the Abuse Potential of Purified Botanical Cannabidiol: Self-Administration, Drug Discrimination, and Physical Dependence","volume":"382","author":"Gray","year":"2022","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1001\/jama.2015.6358","article-title":"Cannabinoids for Medical Use: A Systematic Review and Meta-analysis","volume":"313","author":"Whiting","year":"2015","journal-title":"Jama"},{"key":"ref_11","first-page":"e70383","article-title":"Psychiatric effects of cannabidiol, cannabinol, and tetrahydrocannabinol: A narrative review of clinical evidence and risk profiles","volume":"5","author":"Kishi","year":"2026","journal-title":"Psychiatry Clin. Neurosci. Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1039\/C6NP00074F","article-title":"Phytocannabinoids: A unified critical inventory","volume":"33","author":"Meyer","year":"2016","journal-title":"Nat. Prod. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"113282","DOI":"10.1016\/j.phytochem.2022.113282","article-title":"Biosynthetic origins of unusual cannabimimetic phytocannabinoids in Cannabis sativa L: A review","volume":"201","author":"Welling","year":"2022","journal-title":"Phytochemistry"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"102947","DOI":"10.1016\/j.jflm.2025.102947","article-title":"Medical cannabis: Regulatory review in United States, European Union and United Kingdom","volume":"115","author":"Arjun","year":"2025","journal-title":"J. Forensic Leg. Med."},{"key":"ref_15","unstructured":"Office of Medicinal Cannabis (2026, May 26). Office of Medicinal Cannabis. Available online: https:\/\/english.cannabisbureau.nl."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Sun, X. (2023). Research Progress on Cannabinoids in Cannabis (Cannabis sativa L.) in China. Molecules, 28.","DOI":"10.3390\/molecules28093806"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1007\/s40429-022-00438-3","article-title":"Review: Cannabinoids as Medicinals","volume":"9","author":"Khalsa","year":"2022","journal-title":"Curr. Addctn. Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.1111\/epi.13815","article-title":"Quality of Life in Childhood Epilepsy in pediatric patients enrolled in a prospective, open-label clinical study with cannabidiol","volume":"58","author":"Rosenberg","year":"2017","journal-title":"Epilepsia"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Pagano, C., Navarra, G., Coppola, L., Avilia, G., Bifulco, M., and Laezza, C. (2022). Cannabinoids: Therapeutic Use in Clinical Practice. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23063344"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Atalay, S., Jarocka-Karpowicz, I., and Skrzydlewska, E. (2020). Antioxidative and Anti-Inflammatory Properties of Cannabidiol. Antioxidants, 9.","DOI":"10.3390\/antiox9010021"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1691428","DOI":"10.1155\/2018\/1691428","article-title":"Cannabis sativa L. and Nonpsychoactive Cannabinoids: Their Chemistry and Role against Oxidative Stress, Inflammation, and Cancer","volume":"2018","author":"Pellati","year":"2018","journal-title":"BioMed Res. Int."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.tips.2024.12.005","article-title":"Therapeutic potential of cannabidiol polypharmacology in neuropsychiatric disorders","volume":"46","author":"Manzoni","year":"2025","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1007\/s12325-019-01074-6","article-title":"Examination of a New Delivery Approach for Oral Cannabidiol in Healthy Subjects: A Randomized, Double-Blinded, Placebo-Controlled Pharmacokinetics Study","volume":"36","author":"Patrician","year":"2019","journal-title":"Adv. Ther."},{"key":"ref_24","first-page":"549","article-title":"Chronic Cannabidiol Administration Mitigates Excessive Daytime Sleepiness and Fatigue in Patients with Primary Hypertension: Insights from a Randomized Crossover Trial","volume":"10","author":"Dujic","year":"2025","journal-title":"Cannabis Cannabinoid Res."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Batinic, A., Sutlovi\u0107, D., Kuret, S., Matana, A., Kumric, M., Bozic, J., and Dujic, Z. (2023). Trial of a Novel Oral Cannabinoid Formulation in Patients with Hypertension: A Double-Blind, Placebo-Controlled Pharmacogenetic Study. Pharmaceuticals, 16.","DOI":"10.3390\/ph16050645"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Batinic, A., Sutlovic, D., Kuret, S., Burcul, F., Kalajzic, N., Matana, A., Dujic, G., Vrdoljak, J., Kumric, M., and Bozic, J. (2023). Differences in Plasma Cannabidiol Concentrations in Women and Men: A Randomized, Placebo-Controlled, Crossover Study. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241210273"},{"key":"ref_27","unstructured":"European Medicines Agency (2026, June 03). Epidyolex (Cannabidiol): EPAR\u2014Product Information. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/epidyolex."},{"key":"ref_28","unstructured":"European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) (2020). Cannabis Legislation in Europe: An Overview, European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)."},{"key":"ref_29","first-page":"285","article-title":"Pharmacology and legal status of cannabidiol","volume":"56","author":"Brunetti","year":"2020","journal-title":"Ann. dell\u2019Istituto Super. Sanita"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/add.15587","article-title":"Regulatory approaches to cannabidiol in the European Union: Are market developments sowing the seeds of confusion?","volume":"117","author":"Hughes","year":"2022","journal-title":"Addiction"},{"key":"ref_31","unstructured":"European Union Drugs Agency (EUDA) (2025). European Drug Report 2025: Cannabis, European Union Drugs Agency."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), Turck, D., Bohn, T., Camara, M., Castenmiller, J., De Henauw, S., Jos, A., Maciuk, A., Mangelsdorf, I., and McNulty, B. (2026). Update of the statement on safety of cannabidiol as a novel food. EFSA J., 24, e9862.","DOI":"10.2903\/j.efsa.2026.9862"},{"key":"ref_33","unstructured":"European Commission (2026, May 25). Novel Food Catalogue. Available online: https:\/\/ec.europa.eu\/food\/food-feed-portal\/screen\/novel-food-catalogue\/search."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"100929","DOI":"10.1016\/j.lanepe.2024.100929","article-title":"Germany\u2019s cannabis act: A catalyst for European drug policy reform?","volume":"42","author":"Manthey","year":"2024","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_35","unstructured":"Federal Institute for Drugs and Medical Devices (BfArM) (2026, May 26). Medical Cannabis\u2014Information for Patients. Available online: https:\/\/www.bfarm.de\/DE\/Bundesopiumstelle\/Medizinisches-Cannabis\/Hinweise-fuer-Patienten\/_node.html."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Weissgerber, A., Hermanns-Clausen, M., and Lamy, E. (2025). Over the counter CBD products in Germany: An exploratory survey about consumption patterns and health related effects. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1571025"},{"key":"ref_37","unstructured":"European Commission (2026, May 25). Novel Food\u2014Food Safety. Available online: https:\/\/food.ec.europa.eu\/food-safety\/novel-food_en."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Torovi\u0107, L., Urumovi\u0107, K., Kobiljski, D., and Sr\u0111enovi\u0107 \u010coni\u0107, B. (2026). Cannabidiol in Food and Food Supplements: Drug, Novel Food and Hazard Triangle. Molecules, 31.","DOI":"10.3390\/molecules31132287"},{"key":"ref_39","unstructured":"Federal Ministry of Health (Germany) (2026, June 14). Act on the Controlled Use of Cannabis and on Amendments to Other Regulations (Cannabis Act\u2014CanG). Available online: https:\/\/www.bundesgesundheitsministerium.de\/service\/gesetze-und-verordnungen\/detail\/cannabisgesetz.html."},{"key":"ref_40","unstructured":"DAC\/NRF Commission (2026, June 14). Deutscher Arzneimittel-Codex (DAC)\/Neues Rezeptur-Formularium (NRF). Available online: https:\/\/dacnrf.pharmazeutische-zeitung.de."},{"key":"ref_41","unstructured":"ABDA\u2014Federal Union of German Associations of Pharmacists (2025). German Pharmacies: Figures Data Facts 2025, ABDA\u2014Federal Union of German Associations of Pharmacists."},{"key":"ref_42","unstructured":"Government of the Netherlands (2026, May 25). Toleration Policy Regarding Soft Drugs and Coffee Shops, Available online: https:\/\/www.government.nl\/themes\/family-health-and-care\/drugs\/toleration-policy-regarding-soft-drugs-and-coffee-shops."},{"key":"ref_43","unstructured":"Office of Medicinal Cannabis (2026, May 26). Types of Medicinal Cannabis. Available online: https:\/\/english.cannabisbureau.nl\/medicinal-cannabis\/types-of-medicinal-cannabis."},{"key":"ref_44","unstructured":"CIBG\u2014Ministry of Health, Welfare and Sport (2026, May 25). Medicinal Cannabis. Available online: https:\/\/english.cannabisbureau.nl\/medicinal-cannabis."},{"key":"ref_45","unstructured":"Netherlands Food and Consumer Product Safety Authority (NVWA) (2026, May 25). Food Supplements and Herbal Supplements. Available online: https:\/\/www.nvwa.nl\/onderwerpen\/voedingssupplementen."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000489287","article-title":"The Trouble with CBD Oil","volume":"1","author":"Hazekamp","year":"2018","journal-title":"Med. Cannabis Cannabinoids"},{"key":"ref_47","unstructured":"National Assembly of the Republic of Slovenia (2026, May 26). Act on Cannabis for Medical and Scientific Purposes (ZKMZN). Available online: https:\/\/www.uradni-list.si."},{"key":"ref_48","unstructured":"Slovenian Agency for Medicinal Products and Medical Devices (JAZMP) (2026, May 26). Act on Cannabis for Medical and Scientific Purposes. Available online: https:\/\/jazmp.si\/konoplja-in-kanabinoidi\/zakon-o-konoplji-za-medicinske-in-znanstvene-namene\/."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s42238-024-00242-y","article-title":"The attitudes, knowledge and confidence of healthcare professionals about cannabis-based products","volume":"6","author":"Russo","year":"2024","journal-title":"J. Cannabis Res."},{"key":"ref_50","unstructured":"Slovenian Agency for Medicinal Products and Medical Devices (JAZMP) (2026, May 26). Access to Cannabinoid Medicines in the Republic of Slovenia. Available online: https:\/\/jazmp.si\/konoplja-in-kanabinoidi\/dostop-do-zdravil-s-kanabinoidi-v-republiki-sloveniji\/."},{"key":"ref_51","unstructured":"Slovenian Agency for Medicinal Products and Medical Devices (JAZMP) (2026, May 26). Cannabidiol (CBD)\u2014Classification, Advertising and Marketing of Products. Available online: https:\/\/jazmp.si\/konoplja-in-kanabinoidi\/kanabidiol-cbd-razvrstitev-oglasevanje-in-promet-z-izdelki\/."},{"key":"ref_52","unstructured":"Library of Congress (2026, May 26). Italy: Strict New Regulations on Hemp Take Effect, Available online: https:\/\/www.loc.gov\/item\/global-legal-monitor\/2025-07-16\/italy-strict-new-regulations-on-hemp-take-effect\/."},{"key":"ref_53","unstructured":"CMS Italy (2026, May 26). Cannabis Law and Legislation in Italy. Available online: https:\/\/cms.law\/en\/int\/expert-guides\/cms-expert-guide-to-a-legal-roadmap-to-cannabis\/italy."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Palermiti, A., Cafaro, A., Barco, S., Bucchioni, P., Franceschini, P., Cusato, J., De Nicol\u00f2, A., Manca, A., De Vivo, E.D., and Russo, E. (2021). Analysis of Cannabinoids Concentration in Cannabis Oil Galenic Preparations: Harmonization between Three Laboratories in Northern Italy. Pharmaceuticals, 14.","DOI":"10.3390\/ph14050462"},{"key":"ref_55","unstructured":"Court of Justice of the European Union (2026, May 26). Case C-663\/18: Criminal Proceedings against B S and C A (Kanavape). Available online: https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/?uri=CELEX:62018CJ0663."},{"key":"ref_56","unstructured":"Italian Ministry of Health (2026, June 14). Uso Medico Della Cannabis, Available online: https:\/\/www.salute.gov.it\/new\/it\/tema\/medicinali-stupefacenti-e-precursori-di-droghe\/uso-medico-della-cannabis."},{"key":"ref_57","unstructured":"Italian Medicines Agency (AIFA) (2026, June 14). Italian Medicines Agency, Available online: https:\/\/www.aifa.gov.it\/en."},{"key":"ref_58","unstructured":"Ministero della Salute (2026, August 02). Prescrizione di Preparazioni Magistrali a Base di Cannabis, Available online: https:\/\/www.salute.gov.it\/new\/it\/tema\/medicinali-stupefacenti-e-precursori-di-droghe\/prescrizione-di-preparazioni-magistrali-base-di\/."},{"key":"ref_59","unstructured":"(2026, May 26). Mission Interminist\u00e9rielle de Lutte contre les Drogues et les Conduites Addictives (MILDECA). CBD. Available online: https:\/\/www.drogues.gouv.fr\/le-cbd."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Casanova, C., Ramier, C., Fortin, D., Carrieri, P., Mancini, J., and Barr\u00e9, T. (2022). Cannabidiol use and perceptions in France: A national survey. BMC Public Health, 22.","DOI":"10.1186\/s12889-022-14057-0"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.pharma.2023.02.002","article-title":"Place of therapeutic cannabis in France and safety data: A literature review","volume":"81","author":"Corso","year":"2023","journal-title":"Ann. Pharm. Fr."},{"key":"ref_62","unstructured":"Finnish Medicines Agency (Fimea) (2026, May 27). Cannabidiol (CBD) Is Controlled as a Medicine in Finland. Available online: https:\/\/fimea.fi\/en\/-\/cannabidiol-cbd-is-controlled-as-a-medicine-in-finland."},{"key":"ref_63","unstructured":"(HZZO), C.H.I.F. (2026, June 30). Basic Reimbursement List of Medicinal Products of the Croatian Health Insurance Fund (Osnovna Lista Lijekova Hrvatskog Zavoda za Zdravstveno Osiguranje). Available online: https:\/\/hzzo.hr\/zdravstvena-zastita\/objavljene-liste-lijekova."},{"key":"ref_64","unstructured":"Ministry of Health of the Republic of Croatia (2015). Ordinance on the Prescribing and Dispensing of Medicinal Products Containing Tetrahydrocannabinol (THC), Dronabinol and Nabilone, Ministry of Health of the Republic of Croatia."},{"key":"ref_65","unstructured":"Croatian Agency for Medicinal Products and Medical Devices (HALMED) (2026, June 07). HALMED\u2014Agency for Medicinal Products and Medical Devices. Available online: https:\/\/www.halmed.hr."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Batinic, A., Curkovic, A., Bukic, J., \u017duntar, I., Kuret, S., Mimica, B., Kalajzic, N., Dujic, G., Glava\u0161-Obrovac, L., and Soldo, A. (2023). Knowledge and Attitudes of Cannabidiol in Croatia among Students, Physicians, and Pharmacists. Pharmacy, 12.","DOI":"10.3390\/pharmacy12010002"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1089\/can.2022.0320","article-title":"Chronic Effects of Oral Cannabidiol Delivery on 24-h Ambulatory Blood Pressure in Patients with Hypertension (HYPER-H21-4): A Randomized, Placebo-Controlled, and Crossover Study","volume":"9","author":"Dujic","year":"2024","journal-title":"Cannabis Cannabinoid Res."},{"key":"ref_68","unstructured":"Government of Italy (2025). Decree-Law No. 48 of 11 April 2025."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"l1141","DOI":"10.1136\/bmj.l1141","article-title":"Medicinal use of cannabis based products and cannabinoids","volume":"365","author":"Freeman","year":"2019","journal-title":"BMJ"},{"key":"ref_70","unstructured":"Government of Canada (2026, June 17). Cannabis Act (S.C. 2018, c.16). Available online: https:\/\/laws-lois.justice.gc.ca\/eng\/acts\/C-24.5\/."},{"key":"ref_71","unstructured":"Health Canada (2026, June 17). For Health Care Professionals: Cannabis and Cannabinoids. Available online: https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-medication\/cannabis\/information-medical-practitioners\/information-health-care-professionals-cannabis-cannabinoids.html."},{"key":"ref_72","first-page":"111","article-title":"Simplified guideline for prescribing medical cannabinoids in primary care","volume":"64","author":"Allan","year":"2018","journal-title":"Can. Fam. Physician"},{"key":"ref_73","unstructured":"Canadian Pharmacists Association (2026, June 17). Cannabis for Medical Purposes: Pharmacists\u2019 Role and Responsibilities. Available online: https:\/\/www.pharmacists.ca."},{"key":"ref_74","unstructured":"(2026, June 17). Therapeutic Goods Administration (TGA). Medicinal Cannabis, Available online: https:\/\/www.tga.gov.au\/products\/unapproved-therapeutic-goods\/medicinal-cannabis."},{"key":"ref_75","unstructured":"Australian Government Department of Health and Aged Care (2026, June 18). Medicinal Cannabis Access Pathways, Available online: https:\/\/www.health.gov.au\/topics\/medicinal-cannabis\/medicinal-cannabis-access-pathways."},{"key":"ref_76","unstructured":"(2026, June 17). Pharmaceutical Benefits Scheme. Cannabidiol, Available online: https:\/\/www.pbs.gov.au\/medicinestatus\/document\/445."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/15\/6123\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T04:14:08Z","timestamp":1786162448000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/15\/6123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":76,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["jcm15156123"],"URL":"https:\/\/doi.org\/10.3390\/jcm15156123","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,6]]}}}